About Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Marburg and Ravn Virus Infection: Monoclonal Antibody Found to Be Effective for Treatment

by Madhumathi Palaniappan on April 6, 2017 at 10:00 AM
Font : A-A+

Marburg and Ravn Virus Infection: Monoclonal Antibody Found to Be Effective for Treatment

Monoclonal antibodies can successfully protect the nonhuman primates against Marburg and Ravn virus even after five days of infection, finds a recent study from the University of Texas Medical Branch at Galveston, Mapp Biopharmaceutical and Vanderbilt University.

The study findings were published in Science Translational Medicine.

Advertisement


There are currently no vaccines or drugs approved for human use to protect against the Marburg and Ravn viruses. These two filoviruses, which are in the same virus family as Ebola, cause severe and often lethal disease in people. The average case fatality rate of Marburg virus disease since the first recognized outbreak in 1967 is 80 percent.

Monoclonal antibodies are a technology that is currently in wide use for treating autoimmune diseases and cancers. There are more than 45 monoclonal antibodies approved by the U.S. Food and Drug Administration and European Medicines Agency.
Advertisement

"In this paper, we demonstrated that one monoclonal antibody is able to protect up to 100 percent of Marburg or Ravn virus-infected non-human primates when the antibody treatment is given up to five days following exposure to a lethal amount of the virus," said UTMB's Thomas Geisbert, professor in the department of microbiology and immunology. "These findings extend the growing body of evidence that monoclonal antibodies can provide protection during advanced stages of disease with highly dangerous viruses and could be useful during an epidemic."

The study was conducted in Biosafety Level (BSL)-4 at UTMB's Galveston National Laboratory. BSL-4 is a highly-restricted area where scientists wear positive pressure protective suits and study pathogens that cause severe and often fatal diseases. UTMB has the only functioning BSL-4 laboratory located on an American university campus.

The 2013 to 2016 Ebola virus epidemic highlighted the troubling lack of preventive or treatment options for filoviruses. Some of the therapeutics used to treat those infected with Ebola were developed and tested in the GNL.

"The level of protection observed by Dr. Geisbert's team with this antibody is very impressive. We plan to advance this product towards human safety testing as quickly as possible," said Larry Zeitlin, president of Mapp Biopharmaceutical Inc.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Lung Transplantation
Baldness can be Cured and Prevented: let us see How!
Drinking Beer or Wine Every Day Could Cause Age-related Diseases
View all
Recommended Reading
News Archive
Date
Category
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Chicken Pox Shigellosis 

Most Popular on Medindia

Sanatogen Post-Nasal Drip Iron Intake Calculator Blood Pressure Calculator Pregnancy Confirmation Calculator Drug Side Effects Calculator Vent Forte (Theophylline) Color Blindness Calculator Daily Calorie Requirements Loram (2 mg) (Lorazepam)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close
ASK A DOCTOR ONLINE